Drug Approval | April 28, 2026
AbbVie seeks FDA nod for subcutaneous SKYRIZI induction in Crohn’s disease
The submission is backed by positive results from the Phase 3 AFFIRM study
The submission is backed by positive results from the Phase 3 AFFIRM study
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The approval was driven by data from the Phase III TULIP-SC trial
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
The webinar series will showcase next-gen imaging technologies, global expert insights, and hands-on sessions on microscopy innovations
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Multi-stakeholder initiative highlights inclusive sports pathways, honours neurodivergent athletes, and calls for systemic reforms
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Collaboration integrates SmartChip PCR technology with cloud-based analytics to enable faster, standardised monitoring of antimicrobial resistance
Subscribe To Our Newsletter & Stay Updated
